StockData

Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$83.98−3.00 (-3.45%)

Close on Nov 18, 2026Market cap $4.70BP/E –Yield 0.00%

Dianthus Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Dianthus Therapeutics

Dianthus Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Dianthus Therapeutics figures

See a number that looks wrong?